Arpraziquantel

Arpraziquantel
Clinical data
Other names(R)-Praziquantel
Drug classAnthelmintic
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H24N2O2
Molar mass312.413 g·mol−1
3D model (JSmol)
  • [H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1
  • InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1
  • Key:FSVJFNAIGNNGKK-KRWDZBQOSA-N

Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, and is a medication which is currently under investigation for the treatment of schistosomiasis in young children since it has less side effects than the usual racemic mixture formulation of praziquantel.[1]

Society and culture

In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children.[1] The applicant for this medicinal product is Merck Europe B.V.[1] It is intended exclusively for markets outside the European Union.[1]

Names

Arpraziquantel is the International nonproprietary name.[2]

References

  1. ^ a b c d "Arpraziquantel". European Medicines Agency. 14 December 2023. Archived from the original on 20 December 2023. Retrieved 20 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

Further reading


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.